An interventional study of PRX S Treatment and Active Balancing Cream in Acne Vulgaris, sponsored by Medical University of Silesia. Not yet recruiting at 2 sites in Poland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Acne Vulgaris with a site in Poland — 2 open to participants now, 6 under way, 1 of them phase 3. Acne Vulgaris · Poland.
Among the 25 studies in Acne Vulgaris with a site in Poland, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 with no phase, and was the 24th registered.
792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →2 of the 25 studies in Acne Vulgaris with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Silesia · Sites in Poland
Ages 18–60
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 70 across 674 interventional studies indexed under Acne Vulgaris.
Median enrollment 350 across the 19 interventional studies, 82 across the 6 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
Medical University of Silesia is the lead sponsor of 117 studies on the registry; 28 are open to participants now.
Medical University of Silesia has 2 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies in Acne Vulgaris with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389109Phase 3PPM Services S.A.A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT) | 2026-12 |
| NCT07944274Medical University of SilesiaActive Versus Vehicle Home Care During PRX S Treatment for Mild-to-Moderate Facial Acne | 2027-03-30 |
| NCT07941440Medical University of SilesiaClinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne. | 2027-03-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Acne Vulgaris with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, randomized, parallel-group study aims to evaluate the additional effects of active Balancing Cream compared with its vehicle during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.
A total of 50 participants aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne (Investigator's Global Assessment [IGA] grade 2 or 3) will be enrolled and allocated to two groups of 25 participants each.
Both groups will receive five PRX S treatments at 14-day intervals and use the same Nourishing Cream for Normal and Combination Skin in the morning. In the evening, the experimental group will apply active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide, while the comparator group will use a corresponding cream vehicle without these three ingredients.
The primary outcome is the change from baseline in the total number of facial inflammatory lesions (papules and pustules), assessed two weeks after the fifth PRX S treatment. Secondary assessments include acne severity, non-inflammatory lesion counts, skin biophysical and imaging measurements, and treatment safety.
Clinical and instrumental assessments will be performed at baseline (T0), approximately day 42 (T1), approximately day 70 (T2), and two months after T2 (T3).
The study is designed to assess the additional benefit of active Balancing Cream compared with its vehicle under identical PRX S treatment conditions, rather than the independent efficacy of PRX S.
This prospective, randomized, two-arm, parallel-group clinical study will investigate whether active Balancing Cream provides additional clinical and instrumental benefits compared with its corresponding vehicle when used as adjunctive home care during a standardized series of five PRX S treatments in adults with mild-to-moderate facial acne.
**Study Design and Participants**
The study will include 50 adults aged 18-60 years with dermatologist-confirmed mild-to-moderate facial acne, defined as Investigator's Global Assessment (IGA) grade 2 or 3 and at least five inflammatory lesions (papules and pustules) on the face.
Following eligibility assessment, written informed consent, and baseline measurements, participants will be randomized in a 1:1 ratio to two parallel treatment groups, with 25 participants planned per group. Randomization is planned using computer-generated permuted blocks of varying sizes, stratified by baseline IGA grade (2 or 3). Allocation concealment and masking procedures will be finalized and approved before enrollment.
**Treatment Groups**
Group A (Experimental): Participants will receive five PRX S treatments and use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening.
Group B (Vehicle Comparator): Participants will receive the same five PRX S treatments and use the same Nourishing Cream in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening.
PRX S will be applied externally to the facial skin on days 0, 14, 28, 42, and 56, according to the manufacturer's instructions and a standardized treatment procedure. Both groups will follow identical cleansing and photoprotection recommendations. Assigned home care will continue from baseline (T0) through the final follow-up visit (T3).
The study interventions differ only in the assigned Balancing Cream formulation. The comparator vehicle is not intended to represent a placebo for the PRX S treatment.
**Assessment Schedule**
Clinical and instrumental assessments will be conducted at four time points:
**Clinical and Instrumental Assessments**
Clinical evaluations will include counts of inflammatory facial lesions (papules and pustules), non-inflammatory lesions (open and closed comedones), and acne severity according to the IGA scale.
The instrumental assessment panel will include:
Measurements will be performed on predefined facial areas under standardized conditions.
**Primary Outcome and Statistical Analysis**
The primary outcome is the individual change in total facial inflammatory lesion count from baseline (T0) to T2, calculated as the number of papules and pustules at T2 minus the corresponding baseline count.
The primary analysis will compare the experimental and vehicle groups using analysis of covariance (ANCOVA), adjusting for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).
A negative adjusted difference between the experimental and comparator groups will favor the active Balancing Cream.
Secondary outcomes will include changes in non-inflammatory lesion counts, percentage reduction in inflammatory lesions, IGA scores and response rates, longitudinal skin biophysical parameters, imaging measurements, and safety outcomes. Secondary analyses will be exploratory.
**Safety Monitoring**
Treatment tolerability, adverse events, adherence to assigned home care, and concomitant acne treatments will be monitored throughout the study.
Participants experiencing clinically significant irritation, allergic reactions, infection, or acne worsening will undergo dermatological assessment. Treatment interruption, discontinuation, or rescue therapy will be implemented when clinically indicated.
The study will evaluate the added effect of the three ingredients present in active Balancing Cream within a common PRX S treatment and home-care regimen. It is not designed to determine the independent efficacy of PRX S compared with no PRX S treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). In addition, participants will use Nourishing Cream for Normal and Combination Skin in the morning and active Balancing Cream containing azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3).
Procedure: PRX S Treatment · Other: Active Balancing Cream · Other: Nourishing Cream for Normal and Combination Skin
Participants in this arm will receive the same five PRX S treatments applied to the facial skin at 14-day intervals (days 0, 14, 28, 42, and 56). Participants will use the same Nourishing Cream for Normal and Combination Skin in the morning and a corresponding Balancing Cream vehicle without azelaic acid, salicylic acid, and niacinamide in the evening, from baseline (T0) through the final follow-up visit (T3). The vehicle serves as a comparator for the active Balancing Cream, not for PRX S treatment.
Procedure: PRX S Treatment · Other: Balancing Cream Vehicle · Other: Nourishing Cream for Normal and Combination Skin
PRX S is a professional topical treatment applied to the facial skin after product activation according to the manufacturer's instructions and a standardized procedure. Participants will receive five treatment sessions at 14-day intervals on days 0, 14, 28, 42, and 56. The same PRX S treatment protocol will be used in both study arms.
Active Balancing Cream is a topical facial cream containing azelaic acid, salicylic acid, and niacinamide. Participants assigned to the experimental arm will apply the cream to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The cream will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.
Balancing Cream Vehicle is a corresponding topical facial cream formulation without azelaic acid, salicylic acid, and niacinamide. Participants assigned to the comparator arm will apply the vehicle to the facial skin in the evening as part of their home-care regimen, from baseline (T0) through the final follow-up visit (T3). The vehicle will be used alongside five PRX S treatments and morning application of Nourishing Cream for Normal and Combination Skin.
Nourishing Cream for Normal and Combination Skin is a topical facial moisturizer used as standardized morning home care in both study arms. Participants will apply the cream in the morning from baseline (T0) through the final follow-up visit (T3), alongside their assigned evening Balancing Cream formulation and five PRX S treatments.
Change From Baseline in Facial Inflammatory Lesion Count
Absolute individual change in the total number of facial inflammatory lesions (papules and pustules), calculated as the lesion count at T2 minus the baseline count at T0. The unit of measurement is number of lesions. Negative values indicate improvement. The primary comparison between active Balancing Cream and vehicle groups will use ANCOVA adjusted for baseline inflammatory lesion count and baseline IGA stratum (2 or 3).
Time frame: Baseline (Day 0) and 2 weeks after the fifth PRX S treatment (approximately Day 70).
Change From Baseline in Facial Non-Inflammatory Lesion Count
Change from baseline in the total number of facial non-inflammatory acne lesions, including open and closed comedones. The unit of measurement is number of lesions.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Percentage Reduction in Facial Inflammatory Lesion Count
Percentage reduction in the total number of facial papules and pustules relative to baseline, calculated as 100 × (baseline lesion count - follow-up lesion count) / baseline lesion count.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Inflammatory Lesion Count at Day 42 and Final Follow-Up
Absolute change in the total number of facial inflammatory lesions (papules and pustules) from baseline to T1 and T3. The unit of measurement is number of lesions. Negative values indicate improvement.
Time frame: Baseline (Day 0), approximately Day 42, and 2 calendar months after the Day 70 assessment.
Investigator's Global Assessment (IGA) of Acne Severity
Facial acne severity assessed using the Investigator's Global Assessment (IGA), an ordinal scale from 0 to 4. The distribution of IGA grades and changes over time will be evaluated.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Proportion of Participants Achieving IGA Grade 0 or 1
Percentage of participants achieving an Investigator's Global Assessment (IGA) grade of 0 or 1 at each follow-up assessment.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Proportion of Participants Achieving IGA Treatment Success
Percentage of participants achieving an IGA grade of 0 or 1 together with an improvement of at least 2 grades from baseline. Results will be described according to baseline IGA grade (2 or 3).
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Sebum Level
Skin sebum level measured by sebumetry in standardized facial areas. Results will be expressed in micrograms per square centimeter (µg/cm²).
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Skin Hydration
Skin hydration assessed by corneometry in standardized facial areas. Results will be expressed in arbitrary units.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Skin Elasticity (Cutometer R2)
Skin elasticity assessed using the Cutometer R2 parameter in standardized facial areas. R2 is a dimensionless measurement.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Dermal Thickness
Dermal thickness assessed by skin ultrasonography in standardized facial areas. Results will be expressed in millimeters (mm).
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Dermal Echogenicity
Dermal echogenicity assessed by skin ultrasonography under standardized measurement settings. Results will be expressed in arbitrary units.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Incidence of Adverse Events During Treatment and Follow-Up
Number and percentage of participants experiencing adverse events, including local skin reactions and acne worsening. Adverse event severity, seriousness, relationship to study interventions, treatment interruptions, discontinuations, and rescue therapy will be recorded.
Time frame: From the first study intervention (Day 0) through the final follow-up visit, approximately 2 calendar months after Day 70.
Change From Baseline in Facial Skin Pore Parameters Assessed by Antera 3D
Changes in facial skin pore parameters assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D pore-related outputs.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Texture Assessed by Antera 3D
Changes in facial skin texture assessed by Antera 3D imaging in standardized facial areas. Measurements will be performed at baseline and scheduled follow-up visits using prespecified skin texture parameters.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Change From Baseline in Facial Skin Roughness Assessed by Antera 3D
Changes in facial skin roughness assessed using Antera 3D imaging in standardized facial areas at baseline and follow-up visits. The assessment will use prespecified Antera 3D roughness parameters.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Standardized Facial Photography Using Fotomedicus
Standardized facial photographs will be obtained using the Fotomedicus system at baseline and scheduled follow-up visits to document facial skin appearance and visible acne lesions over time.
Time frame: Baseline (Day 0), approximately Day 42, approximately Day 70, and 2 calendar months after the Day 70 assessment.
Plan to share: Yes — De-identified individual participant data and the accompanying data dictionary will be made available to researchers upon reasonable request, subject to participant consent and the applicable data-sharing policies of the Medical University of Silesia in Katowice.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Following publication of the study results, with no predetermined end date for considering data access requests.
Access criteria: Access to de-identified individual participant data and the data dictionary will be considered upon reasonable request, subject to participant consent and the applicable policies of the Medical University of Silesia in Katowice.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.
Of 58 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 3 months is below that.
Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Silesia →